| 名称 | Lorlatinib |
| 描述 | Lorlatinib (PF-6463922) is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. |
| 细胞实验 | Cells are seeded in 96-well plates in growth medium containing 10% FBS and are cultured overnight at 37°C. The following day, serial dilutions of PF-06463922 or appropriate controls are added to the designated wells, and cells are incubated at 37°C for 72 h. A CellTiter-Glo assay is performed to determine the relative cell numbers. IC50 values are calculated by concentration-response curve fitting using a four-parameter analytical method. |
| 激酶实验 | Recombinant human wild-type and mutant ALK kinase domain proteins (amino acids 1093–1411) are produced in-house using baculoviral expression, preactivated via autophosphorylation with MgATP, and assayed for kinase activity using a microfluidic mobility shift assay. The reactions contained 1.3 nM wild-type ALK or 0.5 nM mutant ALK (appropriate to produce 15-20% phosphorylation of peptide substrate after 1 h of reaction), 3 μM 5-FAM-KKSRGDYMTMQIG-CONH2), 5 mM MgCl2, and the Km level of ATP in 25 mM Hepes, pH 7.1. The inhibitors are shown to be ATP-competitive from kinetic and crystallographic studies. The Ki values are calculated by fitting the conversion (%) to a competitive inhibition equation. ROS1 enzyme is assayed as described above for ALK, except using 0.25 nM recombinant human ROS1 catalytic domain (amino acids 1883-2347). Kinase inhibitor selectivity is evaluated using a 206-kinase panel. |
| 体外活性 | 在含有SLC34A2-ROS1 融合物的HCC78人NSCLC细胞和表达人CD74-ROS1的BaF3-CD74-ROS1细胞中,PF-06463922能够抑制细胞增殖,同时诱导细胞凋亡。在含有非突变型ALK或突变型ALK融合物的NSCLC 细胞中, PF-06463922能够抑制细胞增殖,同时诱导细胞凋亡。对ALK和大量ALK临床突变型（IC50=0.2 -77 nM）, PF-06463922表现出明显的细胞活性。 |
| 体内活性 | 在表达人CD74-ROS1 和 Fig-ROS1的NIH3T3异种移植模型中,PF-06463922通过抑制ROS1磷酸化和下游信号分子,以及对周期蛋白D1的抑制发挥作用,能够抑制细胞增殖.在负荷肿瘤移植物,过表达EML4-ALK,EML4-ALK-L1196M,EML4-ALK-G1269A,EML4-ALK-G1202R 或NPM-ALK的小鼠体内,PF-06463922表现出明显的抗肿瘤活性. |
| 存储条件 | keep away from moisture,store under nitrogen,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.92 mM), Sonication is recommended.
Ethanol : 40.6 mg/mL (99.9 mM), Sonication is recommended.
DMSO : 13 mg/mL (31.99 mM), Sonication is recommended.
|
| 关键字 | TyrosineKinases | Tyrosine Kinases | tyrosine | third-generation | ROSKinase | ROS1 | ROS Kinase | ROS | PF6463922 | PF06463922 | PF 6463922 | PF 06463922 | NSCLC | Neuroblastoma | mutation | LTK (TYK1) | Lorlatinib | kinase | Inhibitor | inhibit | Cluster of differentiation 246 | CD246 | Carcinoma | brain-penetrant | Apoptosis | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | ALK (L1196M) | ALK |
| 相关产品 | Allopurinol | Urea | Kaolin | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Metronidazole | Dextran sulfate sodium salt (MW 5000) | Stavudine | Ethoxyquin | Tamoxifen | Ethyl linoleate |
| 相关库 | 抑制剂库 | 经典已知活性库 | 抗癌活性化合物库 | 已知活性化合物库 | EMA 上市药物库 | 激酶抑制剂库 | FDA 上市药物库 | 免疫/炎症分子化合物库 | 酪氨酸激酶分子库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库 |